News
AKRO
54.65
0.00%
0.00
NextCure To Merge With Avere Therapuetics In All-Stock Deal; NXTC Holders To Receive A Contingent Value Right For 90% Of Net Proceeds From Any Future License, Divestiture Or Monetization Of Its Pipeline Assets And Programs For Two Years; NXTC Also Announces $320M Private Placement
Benzinga · 07/14 10:05
Cantor Fitzgerald Suspends Overweight Rating on Akero Therapeutics
Benzinga · 12/10/2025 13:56
Akero Therapeutics Announces Merger and Delisting Plans
TipRanks · 12/09/2025 14:27
*Novo Nordisk Has Acquired Akero For $54 a Share Plus Additional $6 a Share Based on Milestones
Dow Jones · 12/09/2025 13:54
Weekly Report: what happened at AKRO last week (1201-1205)?
Weekly Report · 12/08/2025 09:05
Akero Therapeutics Shareholders Approve Novo Nordisk Merger
TipRanks · 12/03/2025 15:58
Akero Therapeutics Shareholders Approved Proposed Takeover By Novo Nordisk
Benzinga · 12/03/2025 15:46
NVO,LLY: Shares Drop as Word Health Organization Calls for Cheaper Versions of Weight-Loss Drugs
TipRanks · 12/01/2025 17:54
Weekly Report: what happened at AKRO last week (1124-1128)?
Weekly Report · 12/01/2025 09:05
Weekly Report: what happened at AKRO last week (1117-1121)?
Weekly Report · 11/24/2025 09:05
More
Webull provides a variety of real-time AKRO stock news. You can receive the latest news about Akero Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About AKRO
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.